GI Cell
Latest round
- Series B
Last raised
- Apr 2021
Total raised
- $62M
Investors
- 11
About GI Cell
Founded in 2018 and based in Seongnam, South Korea, GI Cell, Inc. operates as a biotechnology company specializing in the research and development of immuno-cancer cell therapy drugs. In June 2021, its GMP facility was completed. In July 2020, it researched collaboration with Miltenyi Biotec Inc. Chun Pyo Hong is the company's CEO and he is a postdoctoral assistant at the University of Minnesota. The company has partnerships with the International Vaccine Institute(IVI), Samsung Biologics, and GI-BIOME.P NK® platform for NK cell therapy, Nano NK® platform for NK cell therapy, X-Pres T Cell® platform for T cell therapy, and NKpure Expander® platform for optimized cultivation of immune cell.
Who invested in GI Cell
11 investors across 3 rounds
See all investors in GI Cell
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about GI Cell
Who invested in GI Cell?
GI Cell has 11 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has GI Cell raised?
GI Cell has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did GI Cell last raise money?
GI Cell's most recent round on record is a Series B, in Apr 2021.
What does GI Cell do?
Founded in 2018 and based in Seongnam, South Korea, GI Cell, Inc.
Where is GI Cell headquartered?
GI Cell is headquartered in Seongnam, South Korea.
Which VCs invest in companies like GI Cell?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at GI Cell's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like GI Cell? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.